Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „ponatinib“
Suchtreffer
Begriffe & Kennungen
Iclusig · 4.5 · 55 ponatinib AUC0-∞ and Cmax values that were 78% and 47% higher, respectively, than those seen when ponatinib
Eintrag öffnenIclusig · 4.5 · CYP3A inhibitors Ponatinib is metabolized by CYP3A4. Co-administration of a single 15 mg oral dose of Iclusig
Eintrag öffnenIclusig · 4.5 · CYP3A inhibitors Ponatinib is metabolized by CYP3A4. Co-administration of a single 15 mg oral dose of Iclusig
Eintrag öffnenIclusig · 4.5 · Substances that may decrease ponatinib serum concentrations
Eintrag öffnenIclusig · 4.5 · Substances that may decrease ponatinib serum concentrations
Eintrag öffnenIclusig · 4.5 · Substances that may have their serum concentrations altered by ponatinib
Eintrag öffnenIclusig · 4.5 · Substances that may have their serum concentrations altered by ponatinib
Eintrag öffnenIclusig · 4.5 · Substances that may increase ponatinib serum concentrations
Eintrag öffnenIclusig · 4.5 · Substances that may increase ponatinib serum concentrations
Eintrag öffnenIclusig · 4.5 · Transporter substrates In vitro, ponatinib is an inhibitor of P-gp and BCRP. Therefore, ponatinib may have the
Eintrag öffnenIclusig · 4.5 · Transporter substrates In vitro, ponatinib is an inhibitor of P-gp and BCRP. Therefore, ponatinib may have the
Eintrag öffnenIclusig · 4.8 · 23 Ponatinib in combination with reduced- System Organ Class Frequency intensity chemotherapy Adverse reaction
Eintrag öffnenIclusig · 4.8 · 24 Ponatinib in combination with reduced- System Organ Class Frequency intensity chemotherapy Adverse reaction
Eintrag öffnenIclusig · 4.8 · 63 Ponatinib in combination with reduced- System organ class Frequency intensity chemotherapy Adverse reaction
Eintrag öffnenIclusig · 4.8 · 64 Ponatinib in combination with reduced- System organ class Frequency intensity chemotherapy Adverse reaction
Eintrag öffnenIclusig · 4.8 · Hepatotoxicity Events of hepatotoxicity occurred in 64% of patients who have received ponatinib in combination
Eintrag öffnenIclusig · 4.8 · Hepatotoxicity Events of hepatotoxicity occurred in 64% of patients who have received ponatinib in combination
Eintrag öffnenIclusig · 4.8 · Myelosuppression events were reported in 83% of ponatinib-treated patients in PhALLCON, 63% of ponatinib-treat
Eintrag öffnenIclusig · 4.8 · Myelosuppression events were reported in 83% of ponatinib-treated patients in PhALLCON, 63% of ponatinib-treat
Eintrag öffnenIclusig · 4.8 · Paediatric population The safety of ponatinib monotherapy in paediatric patients has been evaluated in a phase
Eintrag öffnen